Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
29 mars 2024 15h20 HE
|
Vincerx Pharma, Inc.
VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00 PM...
Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
05 mars 2024 16h31 HE
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
07 janv. 2024 15h00 HE
|
Vincerx Pharma, Inc.
Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma...
Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023
10 déc. 2023 12h00 HE
|
Vincerx Pharma, Inc.
Poster on VIP943, a novel CD123-targeted antibody-drug conjugate (ADC) from our VersAptx™ platform, showcases selectivity, activity, and safety of VIP943 Poster on VIP924, a first-in-class...
Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
14 nov. 2023 07h00 HE
|
Vincerx Pharma, Inc.
Phase 1 dose escalation for VIP943 - first antibody-drug conjugate (ADC) from VersAptx™, versatile and adaptable, next-generation bioconjugation platform - moves quickly into 2nd cohort Phase 1 dose...
Vincerx Pharma To Present Three Posters at ASH 2023 in December
02 nov. 2023 09h10 HE
|
Vincerx Pharma, Inc.
VIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1 VIP924 poster shows this novel CXCR5-ADC compares favorably with other ADCs in clinical development ...
Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023
19 sept. 2023 07h00 HE
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943
14 sept. 2023 07h00 HE
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer...
Vincerx Pharma Announces FDA Clearance of IND for VIP943
22 août 2023 07h30 HE
|
Vincerx Pharma, Inc.
Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx’ first candidate from next-generation ADC platform and its second IND clearance within 8 months, highlighting Vincerx’s development...
Vincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update
07 août 2023 09h25 HE
|
Vincerx Pharma, Inc.
IND Application filed for potential best-in-class ADC, VIP943; Phase 1 trial expected to begin Q4 2023 Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class SMDC ...